# Casodex 150-mg Compassionate Use Trial for Subjects With Prostate Cancer

> **NCT00636259** · — · NO_LONGER_AVAILABLE · sponsor: **AstraZeneca**

## Conditions studied

- Adenocarcinoma of the Prostate

## Interventions

- **DRUG:** Bicalutamide (Casodex)

## Key facts

- **NCT ID:** NCT00636259
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2008-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00636259

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00636259, "Casodex 150-mg Compassionate Use Trial for Subjects With Prostate Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00636259. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*